** Shares of biotechnology firm AnaptysBio fall ~29% to $21.99 premarket

** Pharma giant Eli Lilly , in an investor presentation, discloses it has dropped ANAB's PD-1 agonist peresolimab to treat rheumatoid arthritis from its pipeline

** "The clinical program's discontinuation is a negative for perception of ANAB's PD-1 agonist rosnilimab," analysts at Leerink Partners wrote in a note

** As of last close, ANAB up ~44% YTD

(Reporting by Manya Saini in Bengaluru)

((Manya.Saini@thomsonreuters.com))